DMPK Challenges and Strategies for Developing Oligonucleotide Drugs

Watch the Webinar

Learn Key Strategies for Tackling Oligo Challenges & Accelerating Your Program

In this joint webinar from WuXi AppTec and AAPS, we explore the complexity and technical challenges associated with oligonucleotide PK evaluation systems. Follow along as WuXi AppTec’s Shiyan Chen, PhD, Hong Zhang, PhD, and Nan Zhao, PhD, examine the state of oligonucleotide development – including current trends, DMPK strategies, ADME study requirements, metabolite identification and profiling, and bioanalysis platforms – as well as strategies and solutions for advancing your own oligonucleotide program. 

WuXi AppTec DMPK Services

WuXi AppTec is a global leader in preclinical drug development testing and world-class expert in DMPK & ADME. We are a full-service, end-to-end testing partner, have screened tens of thousands of oligonucleotide molecules, and supported several through the IND application process.

Asset 1


DPMK Scientists



Global Clients

Asset 1-1


Oligo Molecules